Latest Biotech News

A study in Nature Biomedical Engineering reported that engineered outer membrane vesicles (OMVs) can boost CAR‑T cell activity against solid tumors. Researchers modified bacterial OMVs to deliver...

A preclinical study published in Nature Communications demonstrated boron neutron capture therapy (BNCT) can preserve immune cell integrity while triggering robust anti-tumor immune responses in...

Eli Lilly agreed to acquire Ventyx Biosciences for roughly $1.2 billion, taking control of a clinical-stage oral NLRP3 inhibitor program that targets inflammatory pathways implicated across...

Alumis reported positive Phase III results for envudeucitinib, a selective oral TYK2 inhibitor, meeting co‑primary endpoints in two pivotal trials for moderate-to-severe plaque psoriasis. The...

GSK and development partner Ionis announced positive topline results from two pivotal Phase III studies of bepirovirsen, an antisense oligonucleotide for chronic hepatitis B that met its main...

Amgen struck deals to bolster its oncology pipeline by acquiring Dark Blue Therapeutics and inking related European partnerships that add targeted protein degradation programs and novel cancer...

Sanofi signed a collaboration with Earendil Labs worth up to $2.56 billion to discover and develop bispecific antibodies for autoimmune and inflammatory diseases using Earendil’s AI-driven...

Eli Lilly expanded its obesity playbook with a licensing agreement with Nimbus Therapeutics worth up to $1.3 billion to develop an oral obesity therapy, while early clinical data from Arrowhead...

U.S. health officials revised the federal childhood immunization schedule, narrowing routine recommendations and moving several vaccines to risk‑based or shared‑decision categories. The Centers...

OpenAI launched ChatGPT Health, a dedicated offering for health-related conversations designed to help users navigate personal health information rather than provide diagnoses. The company invited...

Rakuten Medical closed a $100 million financing round to support its photoimmunotherapy platform and an ongoing Phase III trial, with company statements indicating a targeted regulatory filing...

Sophia Genetics and MD Anderson announced a collaboration to co‑develop an NGS‑based oncology assay and AI-driven bioinformatics pipelines to interpret RNA‑seq and multiomic cancer data, with the...

Eli Lilly agreed to buy Ventyx Biosciences for $1.2 billion to add an oral NLRP3 inhibitor to its inflammation and metabolic portfolio. Ventyx’s lead candidate, VTX3232, showed biomarker and...

GSK and development partner Ionis reported positive top-line results from two pivotal Phase 3 studies of bepirovirsen, an antisense oligonucleotide aimed at functional cure for chronic hepatitis...

Amgen struck multiple European deals to bolster its oncology pipeline, including an acquisition of Dark Blue Therapeutics and a license from Disco Pharmaceuticals. The transactions total up to...

Alumis reported positive Phase 3 results for envudeucitinib, a selective oral TYK2 inhibitor, meeting co‑primary endpoints in two pivotal psoriasis studies. The company said the trials showed high...

Arrowhead Pharmaceuticals disclosed early clinical signals from RNAi programs targeting adipose biology that, when paired with Lilly’s tirzepatide (Zepbound), produced larger fat and weight...

Sanofi signed a multi‑year collaboration with Earendil Labs valued up to $2.56 billion to discover bispecific antibodies for autoimmune diseases using Earendil’s AI platform. The pact includes...

Two preclinical immuno‑oncology advances surfaced this week. A Nature Communications study showed Boron Neutron Capture Therapy (BNCT) can preserve immune cell integrity while eliciting anti‑tumor...

Academic and industry groups reported gene‑therapy advances in two distinct domains. University of Pennsylvania researchers published in Nature a cortical gene‑therapy approach that mimics opioid...